Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

We recorded stock-based compensation expense for the three month ended March 31, 2023 and 2022 as follows:

Activity with respect to our Restricted Stock Awards (RSAs) during the three months ended March 31, 2023 was as follows:

	Number of shares			Weighted- average grant-date fair value per share
Outstanding at January 1, 2023		61,888		$	4.72
Granted		90,000			1.10
Cancelled		(26,118	)		1.72

Outstanding and unvested at March 31, 2023		125,770		$	2.75

Activity with respect to our Restricted Stock Units (“RSUs”) during the three months ended March 31, 2023 was as follows:

	Number of shares		Weighted- average grant-date fair value per share
Outstanding at January 1, 2023		2,713,977	$	3.69
Granted		966,503		1.10

Outstanding at March 31, 2023		3,680,480		3.01
Vested and unissued		2,585,247		3.50

Unvested at March 31, 2023		1,095,233	$	1.86